A Phase I, Open-Label, Multicenter, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of HTI-1090 in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2018
At a glance
- Drugs HTI 1090 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Atridia
- 28 Nov 2018 Planned End Date changed from 1 Mar 2019 to 1 Apr 2019.
- 28 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2018 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.